Global Rapid Diagnostics Market

Rapid Diagnostics Market Size, Share, Growth Analysis, By product(kits and equipment), By platform(Immunoassays, Molecular Detection and other platform), By End use(Hospitals & Clinics, Diagnostic Laboratories, Home Care/Self Testing, and Other End Users), By Application(Infectious Diseases Testing, Pregnancy & Fertility Testing, Cardiac Metabolism Testing, Cholesterol Testing), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35A2152 | Region: Global | Published Date: March, 2024
Pages: 219 | Tables: 121 | Figures: 70

Rapid Diagnostics Market Regional Insights

North America, which brought in USD 14.48 billion in sales in 2021, is anticipated to rule the market during the forecast period. The region's point of care diagnostics market is projected to grow as a result of the widespread use of sophisticated point-of-care diagnostics to identify a variety of infectious and chronic diseases as well as the availability of attractive reimbursement policies.

During the forecast period, Europe is expected to develop at a substantial CAGR, dominating the global market share. The introduction of quick diagnostic tools for the timely diagnosis of infectious diseases is the focus of major players in Europe. Additionally, the government has made R&D investments to support the diagnostics industry with regard to the most cutting-edge point-of-care diagnostic testing. These elements contribute to the market expansion in the area. Additionally, the Asia Pacific region is anticipated to grow at a sizable CAGR during the forecast period. The adoption of this kind of diagnostics is likely to be accelerated by the rising incidence of infectious and chronic illnesses throughout the Asia-Pacific.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Rapid Diagnostics Market size was valued at USD 29.26 billion in 2022 and is poised to grow from USD 35.39 billion in 2023 to USD 162.08 billion by 2031, at a CAGR of 20.95% during the forecast period (2024-2031).

the rapid diagnostics market is highly competitive and somewhat fragmented. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Abbott Laboratories', 'Becton, Dickinson and Company', 'Bio-Rad Laboratories, Inc.', 'F. Hoffmann-La Roche Ltd.', 'ACON Laboratories, Inc.', 'Creative Diagnostics', 'Danaher Corporation', 'Thermo Fisher Scientific Inc.', 'BioMérieux S.A.', 'Alfa Scientific Designs, Inc.', 'BTNX Inc.', 'Meridian Bioscience, Inc.', 'and Trinity Biotech plc'

There has been a noticeable rise in the prevalence of chronic illnesses like diabetes, cardiovascular diseases, and numerous infectious diseases. One of the main factors driving the need for point of care diagnostics during the anticipated timeframe is the high prevalence rate of these illnesses. The frequency of diabetes and the other chronic diseases has significantly increased globally, leading to Demand for quick point-of-care diagnostics is expected to increase in order to effectively treat these conditions. favourable market growth for point-of-care diagnostics.

Major market participants are putting more effort into implementing cutting-edge technology like artificial intelligence to create effective point-of-care diagnostics. Lab-on-a-chip platforms, wearable technology, and breakthroughs in smartphone-based technologies have all led to significant improvements in POCT devices. Deep learning systems built on the cloud have prepared the way for coming upheavals. Novel biosensors, microfluidics, and chip technology miniaturisation have advanced the design of new diagnostic systems. One of the main forces behind POCT is lab-on-a-chip technology, notably in the detection of infectious diseases. Several bioassays, including microbiological culture, enzyme-linked immunosorbent assays (ELISA), and polymerase chain reaction (PCB), can now be utilised at the point of care thanks to lab-on-a-chip technology. Therefore, new technologies for POC testing kits manufacturing are expected to boost the market growth during the forecast period.

North America, which brought in USD 14.48 billion in sales in 2021, is anticipated to rule the market during the forecast period. The region's point of care diagnostics market is projected to grow as a result of the widespread use of sophisticated point-of-care diagnostics to identify a variety of infectious and chronic diseases as well as the availability of attractive reimbursement policies.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Rapid Diagnostics Market

Report ID: SQMIG35A2152

$5,300
BUY NOW GET FREE SAMPLE